Business Wire

B2BROKER Launches cTrader Support & Maintenance Service

14.2.2025 10:46:00 EET | Business Wire | Press release

Share

B2BROKER, a leading liquidity and technology provider, has expanded its services with a new cTrader support and maintenance solution, complementing its existing MT4 and MT5 service offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211557945/en/

B2BROKER, a multi-asset liquidity and technology provider, announces the release of its cTrader support and maintenance service. The cTrader Service offers setup, ongoing maintenance, and comprehensive support for your cTrader server, saving you time and financial resources. (Graphic: Business Wire)

cTrader is a widely used multi-asset FOREX/CFD trading platform. Over 300 brokers use it, and adoption is expected to reach 80%. However, high maintenance costs and lengthy team training—often taking up to six months—can pose challenges for brokers.

B2BROKER’s cTrader service solution provides comprehensive technical support and expert dealing training, enabling brokers to streamline operations, reduce costs, and focus on growth.

Notably, clients with an existing cTrader server can benefit from a comprehensive audit service, including a full review of current settings, optimisation recommendations, and seamless transition preparation for B2BROKER’s maintenance.

Here’s a breakdown of the core features included in B2BROKER’s cTrader service:

  • Platform configurations
  • Server support
  • Settings control
  • Trading conditions changes
  • Symbol sessions modification
  • Logs review

Why Choose B2BROKER’s cTrader Service?

B2BROKER’s cTrader service offers a superior alternative to in-house management, providing brokers with expert support, cost savings, and seamless operations.

With extensive expertise in configuring and customising cTrader, B2BROKER’s specialists ensure faster setup, optimised performance, and reduced training requirements—far exceeding the capabilities of most internal teams. This allows brokers to streamline operations without the burden of additional staffing.

The service is also highly cost-effective, offering a more affordable solution than maintaining a full-time in-house team. Clients benefit from 24/7 support and continuous monitoring, ensuring platform stability and peak performance at all times.

B2BROKER takes full responsibility for server infrastructure, employing proactive measures and automated solutions to maintain system reliability and swiftly resolve any issues, keeping trading operations smooth and uninterrupted.

Other benefits of choosing B2BROKER include:

  • Team of Market Experts: B2BROKER’s team is continuously on track with the most recent cTrader updates and best practices.
  • On-call Systems: Customised support levels with proactive tools that guarantee the quickest resolution to any issue.
  • Risk Management Assistance: B2BROKER offers advanced systems for setting risk limits on trading accounts and provides tailored suggestions to every business needs.
  • Direct Communication: Brokers can enjoy direct communication channels with cTrader managers to efficiently deal with all necessary liaisons.
  • Extended Knowledge Base: Clients can access valuable resources for continuous learning and support, including Zendesk Knowledge Base and a dedicated YouTube channel.
  • Training Services: B2BROKER’s team will train the client’s technicians in all aspects of platform customisation and remain available for consultations.

One Solution That Suits All Business Models

B2BROKER recognises that every trading business has unique requirements. Therefore, whether a broker operates independently with cTrader technology or as a standalone entity, B2BROKER offers flexible service plans tailored to diverse business models, ensuring optimised performance and expert support.

“We’ve been in the trading technology field for over a decade, growing alongside our partners at Spotware, the creators of cTrader. We were among the first to launch a cTrader white label solution, and we've recently added a cTrader prop trading white label solution to our offerings. I'm proud to say that our long-standing relationship with Spotware's excellent team enables us to guarantee outstanding service.

“Let us take care of everything—from the setup to the daily management of your cTrader servers—so you can focus on achieving your business goals with confidence.”

Arthur Azizov, CEO & Founder of B2BROKER

Start with B2BROKER’s Professional cTrader Service

Choosing B2BROKER’s cTrader maintenance offers professional service to the trading platform, allowing brokers to focus on core business activities and ensuring that all operations are managed by comprehensive support and advanced tools.

Learn more about B2BROKER’s cTrader server service here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211557945/en/

Contacts

sales@B2BROKER.com
+44 208 068 8636

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye